For some patients with systemic lupus erythematosus, regular repeated treatment with rituximab may prevent disease flare, according to a study from Cassia et al.
Biologics May Prevent Cardiovascular Events in RA Patients
RA patients experience a higher rate of cardiovascular disease (CVD) events than controls. In a new study, Karpouzas et al. determined that current biologic disease-modifying anti-rheumatic drug use is associated with reduced long-term CVD risk, protective calcification of noncalcified lesions and a lower likelihood of new plaque formation in patients with early atherosclerosis.
The Problem with Peer Review
I should have paid more attention in medical school. If I had, I might have remembered enough about basic pathophysiology to know why everyone was suddenly pulling their patients off of lisinopril. For those of you who need a quick primer: When the pressure in the renal artery drops, the kidney secretes renin. Working together,…
Lenabasum for Diffuse Cutaneous Systemic Sclerosis
In a new study, Spiera et al. assessed the safety and efficacy of lenabasum, a synthetic, orally administered agonist of cannabinoid receptor 2 that modulates the endocannabinoid system to activate the resolution phase of innate immune responses, in diffuse cutaneous systemic sclerosis…
The Half-Life of the Truth
My fellow was laughing at me. By itself, I don’t think this was an unusual occurrence. I am quite certain that my fellows laugh at me all the time. That said, when such laughter is called for, I am accustomed to a certain protocol being observed. In general, I expect the laughter to be contained,…
Some Drug Trials Resume after Declines During Pandemic
(Reuters)—Pharmaceutical companies have ramped up clinical trials in the past month, rebounding from a steep decline in activity following the start of the COVID-19 outbreak, though activity remains below pre-pandemic levels, according to new research shareS with Reuters. The research, which was prepared by clinical trial consulting firm Medidata, shows that new subjects entered trials…
Biosimilar Prescribing Habits in the VA & Academic Settings
In a new study, Baker et al. examined reference product and biosimilar orders, comparing data from a Veterans Affairs Medical Center (VAMC) to those from an academic medical center…
Research Beyond COVID-19: Collateral Damage
COVID-19 has generated an outpouring of fast-paced, late-breaking new developments. The majority of countries (188) around the world have reported cases of COVID-19.1 As of April 1, 2020, the Centers for Disease Control and Prevention had reported cases in every U.S. jurisdiction (50 states, District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands and…
More Money, More Research: Foundation Report Sheds Light on Funding Gaps
The ACR and Rheumatology Research Foundation hope a new report on rheumatic disease research can leverage more money for ACR members, funding future research…
Foundation’s Award Provides Research Opportunity for Community-Based Practitioners
Rheumatologists in community-based practices work closely with patients, which allows them to notice trends and nuances researchers may not. Unfortunately, few opportunities exist for rheumatologists to test their observations through research, in addition to taking care of patients. Limited funding, time constraints and competition from larger academic medical centers are some of the barriers that…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 123
- Next Page »